• FluTrackers.com Inc. does not provide medical advice. Information on this web site is collected from various internet resources, and the FluTrackers board of directors makes no warranty to the safety, efficacy, correctness or completeness of the information posted on this site by any author or poster. The information collated here is for instructional and/or discussion purposes only and is NOT intended to diagnose or treat any disease, illness, or other medical condition. Every individual reader or poster should seek advice from their personal physician/healthcare practitioner before considering or using any interventions that are discussed on this website. By continuing to access this website you agree to consult your personal physican before using any interventions posted on this website, and you agree to hold harmless FluTrackers.com Inc., the board of directors, the members, and all authors and posters for any effects from use of any medication, supplement, vitamin or other substance, device, intervention, etc. mentioned in posts on this website, or other internet venues referenced in posts on this website.
  • We are not asking for any donations. Do not donate to any entity who says they are raising funds for us.

Cureus . Impact of Latent Tuberculosis on Severity and Outcomes in Admitted COVID-19 Patients

tetano

Editor, Senior Moderator
Cureus


. 2021 Nov 25;13(11):e19882.
doi: 10.7759/cureus.19882. eCollection 2021 Nov.
Impact of Latent Tuberculosis on Severity and Outcomes in Admitted COVID-19 Patients


Manu Madan[SUP] 1 [/SUP], Bhvya Baldwa[SUP] 1 [/SUP], Arun Raja[SUP] 1 [/SUP], Rahul Tyagi[SUP] 1 [/SUP], Tanima Dwivedi[SUP] 2 [/SUP], Anant Mohan[SUP] 1 [/SUP], Saurabh Mittal[SUP] 1 [/SUP], Karan Madan[SUP] 1 [/SUP], Vijay Hadda[SUP] 1 [/SUP], Pawan Tiwari[SUP] 1 [/SUP], Randeep Guleria[SUP] 1 [/SUP]



Affiliations

Abstract

Background There is limited data on coronavirus disease 2019 (COVID-19) and latent tuberculosis infection (LTBI). Methodology We analyzed data of admitted COVID-19 patients evaluated for LTBI to examine the impact of LTBI on severity, laboratory parameters, and COVID-19 outcome. Prospectively collected data were analyzed for 60 patients who were administered the Mantoux tuberculosis skin test (TST) using five tuberculin units of purified protein derivative. All patients were administered TST irrespective of Bacille Calmette-Guérin (BCG) vaccination status. Comorbidities, clinical features, radiologic involvement, laboratory parameters, and clinical course were analyzed concerning LTBI. Results The mean age was 45.9 (±15.2) years, and 35 (58.3%) patients had non-severe disease. The vast majority (n = 56/60; 93.3%) had been vaccinated with single-dose BCG in infancy or early childhood, as per national immunization guidelines. LTBI was diagnosed in 15 (25%) patients. LTBI prevalence was lower in severe (n = 1/25; 4%) than non-severe (n = 14/35; 40%) COVID-19 (p = 0.01) patients. LTBI patients had lower percentage neutrophil count, higher lymphocyte percentage, higher monocyte count, lower neutrophil-lymphocyte (NL) ratio, lower alanine aminotransferase, lower C-reactive protein, and lesser radiologic involvement compared to those without LTBI (p < 0.05). Similarly, among the mild COVID-19 subgroup, those with LTBI had higher lymphocyte and monocyte counts and lesser radiologic involvement than those without LTBI (p < 0.05). Conclusions LTBI patients appear to have milder disease, higher lymphocyte and monocyte count, higher NL ratio, and lesser radiographic involvement. This observation needs to be studied in larger studies using interferon release assays.

Keywords: covid-19; covid-19 severity; latent tuberculosis; ltbi; mantoux test.
 
Back
Top Bottom